5 completed, 5 recruiting, 2 terminated, 1 not yet recruiting. 10 Phase 2, 7 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 10 | Recruiting 4, Completed 2, Terminated 2, Not yet recruiting 1, Withdrawn 1 |
| Phase 1 | 7 | Completed 3, Recruiting 2, Terminated 1, Withdrawn 1 |
| Phase 3 | 2 | Completed 1, Recruiting 1 |
Follow RAD1901: new trials by email Literature Review of RAD1901 trials Research Report on RAD1901
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer Biospecimen Collection, Computed Tomography, Elacestrant - Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma | Phase 2 | Not yet recruiting | Jonsson Comprehensive Cancer Center | 50 | 2026-12-18 | 2026-06-09 |
| Ph 2 Elacestrant in ER Positive Uterine Sarcomas Elacestrant - Uterine Sarcoma, Uterine Leiomyosarcoma | Phase 2 | Recruiting | Dana-Farber Cancer Institute | 30 | 2026-03-25 | 2026-05-22 |
| PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA) Capecitabine, Elacestrant - Estrogen-receptor-positive Breast Cancer, Metastatic Breast Cancer | Phase 2 | Recruiting | Kristina A. Fanucci | 297 | 2026-01-16 | 2026-08-26 |
| ERADICATE: A Phase Ib/II Study of Elacestrant Plus Trastuzumab Deruxtecan in Patients With CDK4/6 Inhibitor and Endocrine-resistant HR+/HER2-low or HER2-ultralow Metastatic Breast Cancer Elacestrant, Trastuzumab Deruxtecan - Metastatic Breast Cancer, HER2 Low Breast Carcinoma | Phase 1 / Phase 2 | Recruiting | Kristina A. Fanucci | 65 | 2025-11-17 | 2026-06-10 |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. Everolimus, Elacestrant, Placebo - Advanced Breast Cancer, ER-positive Breast Cancer | Phase 3 | Recruiting | MedSIR | 300 | 2024-12-05 | 2026-08-24 |
| A Study of Samuraciclib and Elacestrant in Participants With Metastatic or Locally Advanced HR+/HER2-negative Breast Cancer Samuraciclib, Elacestrant Dihydrochloride - Metastatic Breast Cancer, Locally Advanced Breast Cancer | Phase 1 / Phase 2 | Completed | Carrick Therapeutics Limited | 49 | 2023-10-09 | 2026-03-23 |
| A Rollover Protocol of Elacestrant, in Combination With Onapristone, for Patients With ER+, PR+, HER2- Advanced or Metastatic Breast Cancer Elacestrant, Onapristone - Breast Cancer | Phase 1 / Phase 2 | Withdrawn | Context Therapeutics Inc. | 2023-06-01 | 2025-04-22 | |
| A PK Study Testing Single Oral Dose of Elacestrant in Subjects With Normal or Severely Impaired Hepatic Function Elacestrant dihydrochloride - Hepatic Impairment | Phase 1 | Completed | Stemline Therapeutics, Inc. | 16 | 2023-03-13 | 2024-11-19 |
| Study of Elacestrant in Combination With Onapristone in Patients With Advanced or Metastatic Breast Cancer Elacestrant, Onapristone - Breast Cancer | Phase 1 / Phase 2 | Terminated | Context Therapeutics Inc. | 4 | 2022-12-02 | 2026-07-21 |
| Study of Abemaciclib and Elacestrant in Participants With Brain Metastasis Due to ER+/HER-2- Breast Cancer Elacestrant, Abemaciclib - Breast Neoplasms, Brain Neoplasms | Phase 1 / Phase 2 | Recruiting | Stemline Therapeutics, Inc. | 73 | 2022-08-31 | 2026-10-09 |
| Phase 3 Trial of Elacestrant Versus Standard of Care for the Treatment of ER+/HER2- Advanced Breast Cancer Elacestrant, Standard of Care - Breast Cancer | Phase 3 | Completed | Stemline Therapeutics, Inc. | 478 | 2019-05-10 | 2025-09-15 |
| Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer RAD1901 - Metastatic Breast Cancer | Phase 1 | Completed | Stemline Therapeutics, Inc. | 16 | 2016-04-01 | 2022-08-18 |
| Study to Evaluate the Safety and Efficacy of RAD1901 in Postmenopausal Women With Moderate to Severe Vasomotor Symptoms RAD1901, Placebo - Vasomotor Symptoms, Hot Flashes | Phase 2 | Terminated | Radius Pharmaceuticals, Inc. | 139 | 2015-12-01 | 2019-03-13 |
| A Study to Evaluate the Effects of RAD1901 in the Treatment of Vasomotor Symptoms in Postmenopausal Women RAD1901, Placebo - Hot Flashes | Phase 2 | Completed | Radius Pharmaceuticals, Inc. | 100 | 2009-03-01 | 2018-09-26 |
Breast Neoplasms (9) · Hot Flashes (2) · Adenosarcoma of the uterus (1) · Brain Diseases (1) · Brain Neoplasms (1) · Breast Diseases (1) · Central Nervous System Diseases (1) · Central Nervous System Neoplasms (1) · Endometrial Neoplasms (1) · Neoplasms (1) · Neoplasms by Site (1) · Perivascular Epithelioid Cell Neoplasms (1) · Sarcoma, Endometrial Stromal (1)
Stemline Therapeutics, Inc. (4) · Context Therapeutics Inc. (2) · Kristina A. Fanucci (2) · Radius Pharmaceuticals, Inc. (2) · Carrick Therapeutics Limited (1) · Dana-Farber Cancer Institute (1) · Jonsson Comprehensive Cancer Center (1) · MedSIR (1)
United States (12) · France (4) · Spain (4) · United Kingdom (4) · Belgium (3) · Greece (3) · Italy (3) · Austria (2) · Germany (2) · South Korea (2) · Argentina (1) · Australia (1) · Brazil (1) · Canada (1) · Czechia (1)
Kristina Fanucci, MD (2) · Antonio Llombart-Cussac, M.D., Ph.D. (1) · Elisabeth GE de Vries, MD (1) · Jordyn Silverstein, MD (1) · Suzanne George, MD (1)
PMID 27575546, PMID 31426673, PMID 32912274, PMID 35584336, PMID 38381994
2015 (1), 2023 (1)